- Home
- NTB vs ARQT Comparison
NTB vs ARQT Comparison
Compare NTB & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTB
- ARQT
- Stock Information
- Founded
- NTB 1858
- ARQT 2016
- Country
- NTB Bermuda
- ARQT United States
- Employees
- NTB N/A
- ARQT N/A
- Industry
- NTB Commercial Banks
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- NTB Finance
- ARQT Health Care
- Exchange
- NTB Nasdaq
- ARQT Nasdaq
- Market Cap
- NTB 1.9B
- ARQT 1.7B
- IPO Year
- NTB 2016
- ARQT 2020
- Fundamental
- Price
- NTB $44.68
- ARQT $14.29
- Analyst Decision
- NTB Buy
- ARQT Strong Buy
- Analyst Count
- NTB 3
- ARQT 7
- Target Price
- NTB $51.33
- ARQT $18.67
- AVG Volume (30 Days)
- NTB 156.6K
- ARQT 1.5M
- Earning Date
- NTB 07-28-2025
- ARQT 08-06-2025
- Dividend Yield
- NTB 4.52%
- ARQT N/A
- EPS Growth
- NTB 14.60
- ARQT N/A
- EPS
- NTB 4.96
- ARQT N/A
- Revenue
- NTB $588,897,000.00
- ARQT $212,819,000.00
- Revenue This Year
- NTB $3.10
- ARQT $61.01
- Revenue Next Year
- NTB $0.34
- ARQT $37.95
- P/E Ratio
- NTB $9.17
- ARQT N/A
- Revenue Growth
- NTB 2.95
- ARQT 100.03
- 52 Week Low
- NTB $33.04
- ARQT $7.86
- 52 Week High
- NTB $46.89
- ARQT $17.75
- Technical
- Relative Strength Index (RSI)
- NTB 47.68
- ARQT 46.02
- Support Level
- NTB $44.11
- ARQT $14.44
- Resistance Level
- NTB $46.38
- ARQT $15.38
- Average True Range (ATR)
- NTB 0.93
- ARQT 0.66
- MACD
- NTB -0.18
- ARQT -0.09
- Stochastic Oscillator
- NTB 23.25
- ARQT 10.19
About NTB Bank of N.T. Butterfield & Son Limited (The) Voting
Bank of N.T Butterfield & Son Ltd is a full-service bank and wealth manager. It operates the business through three geographic segments, Bermuda, Cayman Islands, the Channel Islands and the UK. The company offers banking services, comprised of retail and corporate banking, and wealth management, which consists of trust, private banking, and asset management. The company generates a majority of its revenue from Bermuda, and the Cayman Islands segments.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.